Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis

NCT04643470 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04643470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2020
Completion date
August 26, 2024
Enrollment
177 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis